Phibro Animal Health (NASDAQ:PAHC) Hits New 52-Week High - Time to Buy?

Key Points

• Phibro Animal Health's stock reached a new 52-week high at $42.32, with a trading volume of 215,875 shares, following a close at $40.62.
• Analysts have set varying target prices for the stock, with Bank of America at $27.00 and JPMorgan Chase raising it to $35.00, while Zacks Research upgraded the rating to strong-buy.
• The company reported earnings of $0.57 per share for the last quarter, exceeding estimates, and announced a quarterly dividend of $0.12, indicating a yield of 1.2%.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report)'s stock price hit a new 52-week high on Tuesday . The company traded as high as $42.32 and last traded at $41.94, with a volume of 215875 shares traded. The stock had previously closed at $40.62.

Analysts Set New Price Targets

A number of research firms recently commented on PAHC. Bank of America raised their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $25.00 to $35.00 in a research report on Monday, July 7th. Zacks Research upgraded Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Monday, September 29th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Phibro Animal Health in a report on Tuesday, October 14th. Finally, Morgan Stanley set a $34.00 price target on shares of Phibro Animal Health in a report on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $28.40.

Phibro Animal Health Stock Up 2.3%

The business has a fifty day moving average price of $37.02 and a two-hundred day moving average price of $28.57. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 35.40, a P/E/G ratio of 1.20 and a beta of 0.83.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.05. The firm had revenue of $378.70 million for the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, equities analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd were issued a $0.12 dividend. The ex-dividend date was Wednesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health's dividend payout ratio is currently 40.68%.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,022 shares of the business's stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $40.26, for a total value of $282,705.72. Following the completion of the sale, the chief executive officer directly owned 31,338 shares in the company, valued at approximately $1,261,667.88. The trade was a 18.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 24,622 shares of company stock valued at $995,893 over the last ninety days. 50.13% of the stock is owned by insiders.

Hedge Funds Weigh In On Phibro Animal Health

Several large investors have recently bought and sold shares of the stock. National Bank of Canada FI bought a new position in shares of Phibro Animal Health during the first quarter valued at $30,000. Financial Management Professionals Inc. bought a new stake in shares of Phibro Animal Health during the 2nd quarter valued at $32,000. EverSource Wealth Advisors LLC lifted its stake in shares of Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company's stock valued at $69,000 after purchasing an additional 2,685 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company's stock worth $118,000 after purchasing an additional 4,079 shares during the last quarter. Finally, Quantbot Technologies LP grew its stake in shares of Phibro Animal Health by 53.8% during the first quarter. Quantbot Technologies LP now owns 7,870 shares of the company's stock worth $168,000 after purchasing an additional 2,754 shares during the period. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.